A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Boehringer Ingelheim
UroGen Pharma Ltd.
Astellas Pharma Inc
Merck Sharp & Dohme LLC
Shanghai Escugen Biotechnology Co., Ltd
Palleon Pharmaceuticals, Inc.
Merck Sharp & Dohme LLC
Incyte Corporation
Trishula Therapeutics, Inc.
ALX Oncology Inc.
Incyte Corporation
Genentech, Inc.
Trishula Therapeutics, Inc.
TransThera Sciences (Nanjing), Inc.
NGM Biopharmaceuticals, Inc
Aprea Therapeutics
Revolution Medicines, Inc.
AstraZeneca
Bayer
Multi4 Medical Ab
Astellas Pharma Inc
Hoffmann-La Roche
Janssen Research & Development, LLC
Pfizer
Protara Therapeutics
Protara Therapeutics
Bristol-Myers Squibb
Acepodia Biotech, Inc.
Photocure
Keythera (Suzhou) Pharmaceuticals Co. Ltd
UroGen Pharma Ltd.
Astellas Pharma Inc
DxTerity Diagnostics
Eli Lilly and Company
Genentech, Inc.
Xencor, Inc.
CicloMed LLC
Five Prime Therapeutics, Inc.
TransThera Sciences (Nanjing), Inc.
Chengdu CoenBiotech Co., Ltd
Hoffmann-La Roche
Hoffmann-La Roche
Pfizer
Ikena Oncology
STCube, Inc.
Corvus Pharmaceuticals, Inc.
Processa Pharmaceuticals